ResMed’s Growth Outlook Trails Its Recent Revenue Pace
StockStory points to ResMed’s cash generation as a strength, while analysts expect slower revenue growth over the next 12 months.
Makkler Newsroom · Oct 5, 08:53 PM · 1 min read
ResMed Inc. RMD
NYSEHealth TechnologyUnited States
$239.53+0.64 (+0.27%)
Market closed· · USD · Data may be delayed
- Day's range
- 239.15241.86
- 52-week range
- 180.27277.67
Financial health
– / 5
Analyst view · 30 firms
Buy17 buy · 10 hold · 3 sell
Avg. target $272.76 (+13.9%)
Prices may be delayed and are for informational purposes only - not investment advice.